Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [(68)Ga]PSMA-PET-guided metastasis-directed therapy

PURPOSE: Since the success of prostate-specific membrane antigen-positron emission tomography (PSMA-PET) imaging for patients with oligorecurrent prostate cancer (ORPC), it is increasingly used for radiotherapy as metastasis-directed therapy (MDT). Therefore, we developed a prognostic risk classific...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Eur J Nucl Med Mol Imaging
Autori principali: Vogel, Marco M. E., Kroeze, Stephanie G. C., Henkenberens, Christoph, Schmidt-Hegemann, Nina-Sophie, Kirste, Simon, Becker, Jessica, Burger, Irene A., Derlin, Thorsten, Bartenstein, Peter, Mix, Michael, la Fougère, Christian, Eiber, Matthias, Christiansen, Hans, Belka, Claus, Grosu, Anca L., Müller, Arndt-Christian, Guckenberger, Matthias, Combs, Stephanie E.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer Berlin Heidelberg 2020
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7396407/
https://ncbi.nlm.nih.gov/pubmed/32179961
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00259-020-04760-8
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi